Keating Capital is the lead investor in Series D funding Metabolon
(BUSINESS WIRE) 1 September 2011
Keating Capital, Inc., a pre-IPO fund, announced that on 25 August 2011, there is a $ 4 million investment in the $ 13 million Series D Convertible Preferred Stock round Metabolon, Inc. (http://www.Metabolon.com) (“metabolomics”). Other investors in the Series D round include existing investors Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners.
Founded
in 2000 and is headquartered in Research Triangle Park, North Carolina, is Metabolon a molecular diagnostics and service companies to identify the world’s a novel metabolic profiling technology, advanced bioinformatics and data analysis software to quantify, analyzes and uses biochemical processes within cells. Metabolon end-to-end profiling service is used by leading academic institutions and pharmaceutical, biotechnology, agriculture and consumer goods companies to develop more effective drugs, diagnostic tests, and consumer and agricultural products. Metabolon uses biomarkers through its technology in the development of molecular diagnostic tests to identify the detection and measurement of aggression and the stage of disease such as diabetes and cancer.
Timothy J. Keating, said Keating Capital CEO: “We are pleased to diversify our portfolio with the addition of our first life sciences company, we are pleased to partner with Equity Metabolon, and we believe that the mouth of. company with an outstanding management team, world-class scientific advisory board and blue-chip clients of the company will ultimately lead to major disruptive innovation in the provision of medicines for patients around the world. “
Metabolon’s sixth new Keating Capital portfolio company investments in 2011. With this investment, Keating Capital has now invested a total of $ 23 million in 10 portfolio companies, of which $ 19,400,000 was invested in 2011.
Keating Capital
distribution list to be added, go to http://www.KeatingCapital.com/contact.
About
Keating Capital, Inc. Keating Capital is a business development company in the production of pre-IPO investments in innovative, high-growth private companies that are committed and able to specialize in public. Keating Capital provides private investors with the opportunity in a unique fund that is late in a private company, attend pre-IPO round of funding invested -. An opportunity that was historically reserved for institutional investors
Forward-Looking Statements
This press release may contain statements of a forward-looking nature regarding future events. These forward-looking statements are subject to inherent uncertainties in predicting future results and conditions. These statements reflect Keating Capital’s current beliefs and a number of important factors could cause actual results could differ materially from those contained in this press release, including the factors discussed in “Risk Factors” in terms that are set in Keating Capital’s Form 10-K and Form 10 -Q filed with the Securities and Exchange Commission (“SEC”) and subsequent filings with the SEC. Please note Keating Capital SEC are connected for a more detailed description of risks and uncertainties with its business partners, including but not limited to risks and uncertainties associated with the limited investment in micro-and small-cap companies. With the exception of the U.S. securities laws, Keating Capital acquires no obligation to revise or update any forward-looking statements, whether as a result of new
information, future events or otherwise. The reference to Keating Capital site is provided as a convenience, and the information on this website is not incorporated by reference information contained in this press release.
###
© Copyright 1997 -
, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.